Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS
Home/The Filing Wire/Stoke Therapeutics, Inc./ 424B5

SEC Filing · 424B5

Stoke Therapeutics, Inc.

STOKNASDAQEQUITYCurrent

SEC Filing

Filed Aug 3, 2026Accepted Aug 3, 2026, 5:04 PM EDTCIK 1623526Accession 0001193125-26-330792
View company →Permanent SEC source ↗
Share

Company context

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal

Current securities

STOKNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by BIOTECHNOLOGY VALUE FUND L P regarding Stoke Therapeutics, Inc.Sep 30, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 25, 2026
  3. 4 filingAug 18, 2026
  4. SCHEDULE 13G/A - filed by Lynx1 Capital Management LP regarding Stoke Therapeutics, Inc.Aug 14, 2026
  5. Other EventsAug 3, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.